A. Galietta

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

Rocco Piazza, Roberta Rostagno, Leonardo Scapozza, 2003, The Lancet. Oncology.

Loss of hMSH2 expression in primary breast cancer with p53 alterations.

M. Di Maio, G. Pettinato, A. Galietta, 2004, Oncology reports.

Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib

L. Scapozza, F. Andreoni, C. Gambacorti-Passerini, 2005, Leukemia.

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Guido Marcucci, M. Caligiuri, C. Bloomfield, 2005, Cancer cell.

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Guido Marcucci, Anne E Willis, M. Caligiuri, 2006, Blood.

NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

A. Villa, D. Perrotti, S. Redaelli, 2007, Blood.

TAG-72 expression and clinical outcome in primary breast cancer.

R. Mariani-Costantini, R. Muraro, A. Bianco, 1999, Oncology reports.

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

M. Caligiuri, G. Marcucci, B. Blaser, 2006, Blood.